[go: up one dir, main page]

WO2004076474A3 - Polyethylene glycol modified interferon compositions and methods of use thereof - Google Patents

Polyethylene glycol modified interferon compositions and methods of use thereof Download PDF

Info

Publication number
WO2004076474A3
WO2004076474A3 PCT/US2004/005649 US2004005649W WO2004076474A3 WO 2004076474 A3 WO2004076474 A3 WO 2004076474A3 US 2004005649 W US2004005649 W US 2004005649W WO 2004076474 A3 WO2004076474 A3 WO 2004076474A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyethylene glycol
methods
glycol modified
modified interferon
interferon compositions
Prior art date
Application number
PCT/US2004/005649
Other languages
French (fr)
Other versions
WO2004076474A2 (en
Inventor
Vlasselaer Peter Van
Michael J Roberts
Gary Visor
Stephen A Charles
Original Assignee
Intermune Inc
Vlasselaer Peter Van
Michael J Roberts
Gary Visor
Stephen A Charles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc, Vlasselaer Peter Van, Michael J Roberts, Gary Visor, Stephen A Charles filed Critical Intermune Inc
Priority to EP04714217A priority Critical patent/EP1597278A4/en
Priority to CA002516552A priority patent/CA2516552A1/en
Priority to CNA2004800087851A priority patent/CN1997666A/en
Priority to JP2006503875A priority patent/JP2006519235A/en
Publication of WO2004076474A2 publication Critical patent/WO2004076474A2/en
Publication of WO2004076474A3 publication Critical patent/WO2004076474A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Interferon alpha (IFN-α) linked to a linear polyethylene glycol (PEG) molecule having a nominal molecular weight of about 30 kD, and compositions comprising the same, are provided. The invention further provides methods of treating a viral infection with the subject PEG-modified IFN-α.
PCT/US2004/005649 2003-02-26 2004-02-24 Polyethylene glycol modified interferon compositions and methods of use thereof WO2004076474A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04714217A EP1597278A4 (en) 2003-02-26 2004-02-24 Polyethylene glycol modified interferon compositions and methods of use thereof
CA002516552A CA2516552A1 (en) 2003-02-26 2004-02-24 Polyethylene glycol modified interferon compositions and methods of use thereof
CNA2004800087851A CN1997666A (en) 2003-02-26 2004-02-24 Polyethylene glycol modified interferon compositions and methods of use thereof
JP2006503875A JP2006519235A (en) 2003-02-26 2004-02-24 Polyethylene glycol modified interferon composition and method of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45058703P 2003-02-26 2003-02-26
US60/450,587 2003-02-26

Publications (2)

Publication Number Publication Date
WO2004076474A2 WO2004076474A2 (en) 2004-09-10
WO2004076474A3 true WO2004076474A3 (en) 2005-01-06

Family

ID=32927673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/005649 WO2004076474A2 (en) 2003-02-26 2004-02-24 Polyethylene glycol modified interferon compositions and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1597278A4 (en)
JP (1) JP2006519235A (en)
CN (1) CN1997666A (en)
CA (1) CA2516552A1 (en)
WO (1) WO2004076474A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004224466B2 (en) * 2003-03-28 2008-01-03 Biopolymed Inc. Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
JP2008543943A (en) * 2005-06-20 2008-12-04 ペプゲン コーポレイション Low toxicity long-circulating chimeras of human interferon alpha analogues and interferon tau
CN101002945B (en) 2006-01-20 2012-09-05 清华大学 Novel complex used for treating tumor
CN100475270C (en) 2006-01-20 2009-04-08 清华大学 A kind of medicine for treating tumor and application thereof
BRPI0717674A2 (en) * 2006-11-24 2014-04-08 Cadila Healthcare Ltd 'FORMULATION UNDERSTANDING PEG-INTERFERON ALPHA CONJUGATES, FORMULATION LYOPHILIZATION PROCESS AND LYOPHILIZED FORMULATION'
CN101219219B (en) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 Complex containing vascellum chalone or fragment, preparation method and application thereof
US8597635B2 (en) * 2007-09-04 2013-12-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha-2B modified by polyethylene glycol and methods of preparation thereof
CN101525381B (en) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 Novel recombinant consensus interferon and construction of a high-efficiency expression vector thereof
AU2011220885A1 (en) * 2010-02-25 2012-09-06 Sangart, Inc. Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios
WO2013170386A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
EP3272857B1 (en) * 2015-03-17 2020-08-12 Shigetaka Shimodaira Method for preparing dendritic cell by non-adhesive culture using ifn
US11123436B2 (en) * 2015-07-24 2021-09-21 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
CN107670051A (en) * 2017-10-28 2018-02-09 湖南华腾制药有限公司 A kind of preparation method of polyethyleneglycol modified protein
CN114767835A (en) * 2022-05-18 2022-07-22 北京键凯科技股份有限公司 Pharmaceutical composition for treating colorectal cancer and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0822199A2 (en) * 1994-10-12 1998-02-04 Amgen Inc. N-terminally monopegylated polypeptides and process for their preparation.
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US20030055013A1 (en) * 2001-09-20 2003-03-20 Schering Corporation HCV combination therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU2003297285A1 (en) * 2002-11-18 2004-06-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0822199A2 (en) * 1994-10-12 1998-02-04 Amgen Inc. N-terminally monopegylated polypeptides and process for their preparation.
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US20030055013A1 (en) * 2001-09-20 2003-03-20 Schering Corporation HCV combination therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOSER S ET AL: "Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a", PROTEIN EXPRESSION PURIFICATION, vol. 30, July 2003 (2003-07-01), pages 78 - 87, XP004432807 *
KOZLOWSKI A ET AL: "Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C", BIODRUGS, vol. 15, no. 7, 2001, pages 419 - 429, XP002903517 *
MONKARSH S ET AL: "Positional Isomers of Monopegylated Interferon alpha-2a: Isolation, Characterization, and Biological Activity", ANALYTICAL BIOCHEMISTRY, vol. 247, 1997, pages 434 - 440, XP002092303 *
See also references of EP1597278A4 *

Also Published As

Publication number Publication date
CA2516552A1 (en) 2004-09-10
WO2004076474A2 (en) 2004-09-10
EP1597278A4 (en) 2006-03-22
EP1597278A2 (en) 2005-11-23
JP2006519235A (en) 2006-08-24
CN1997666A (en) 2007-07-11

Similar Documents

Publication Publication Date Title
WO2004076474A3 (en) Polyethylene glycol modified interferon compositions and methods of use thereof
IS8169A (en) New poly (ethylene glycol) altered compounds and their use
EA200400962A1 (en) POLYALKYLENE GLYCOL WITH RESIDUAL FOR CONJUGATION OF BIOLOGICALLY ACTIVE CONNECTION
DE60224296D1 (en) HAIR CARE COMPOSITIONS
DK1454138T3 (en) Immunocytokines with modulated selectivity
DK1517710T3 (en) Pegylated factor VII glycoforms
DE60316842D1 (en) Fluorinated Polyether Compositions
DE60204820D1 (en) Antistatic polymer compositions
ATE369434T1 (en) ADENO-ASSOCIATED VIRUS VECTORS AND THEIR USES
WO2005058366A3 (en) Compositions comprising two different populations of polymer-active agent conjugates
BR0013193A (en) Polymerization of ethylene oxide using metal cyanide catalysts
ATE321804T1 (en) POLYETHERESTERELASTOMER WITH POLYTRIMETHYLENE ETHER SOFT SEGMENT AND TETRAMETHYLENE ESTER HARD SEGMENT
DE60204349D1 (en) 4- (1,3,4-THIADIAZOLYL-2-YL) -1,4-DIAZABIZYKLO- 3.2.2 NONANDERIVATES, THEIR PREPARATION AND THEIR THERAPEUTIC USES
ITMI20000549A0 (en) PROCEDURE FOR THE PREPARATION OF POLYCARBONATE DIOLS WITH HIGH MOLECULAR WEIGHT
FI961536L (en) Method for inactivating viruses in the presence of polyalkylene glycol, as well as the pharmaceutical preparation thus obtained
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
NO20034085D0 (en) Polyethylene mixed with low molecular weight hydrogenated aliphatic hydrocarbons
WO2005084303A3 (en) Interferon-beta polymer conjugates
PL366692A1 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
DE60313786D1 (en) POLY (ETHYLENE GLYCOL) CONJUGATES OF INSULINARY GROWTH FACTOR BINDING PROTEIN-4
DE60238816D1 (en) PROCESS FOR PREPARING ISOBUTYLENE POLYMERS WITH HIGH MOLECULAR WEIGHT
WO2003097677A3 (en) Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus
WO2002077144A3 (en) Hand dishwashing composition
WO2004043884A3 (en) Novel acylating reagents
ITMI20031872A1 (en) POLYESTER COPOLYMERS AND POLYVINYLPYRROLIDONE.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2516552

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006503875

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004714217

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20048087851

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004714217

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004714217

Country of ref document: EP